tradingkey.logo

Pulmonx Corp

LUNG
1.770USD
+0.070+4.12%
Market hours ETQuotes delayed by 15 min
72.12MMarket Cap
LossP/E TTM

Pulmonx Corp

1.770
+0.070+4.12%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Pulmonx Corp

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Pulmonx Corp's Score

Industry at a Glance

Industry Ranking
88 / 210
Overall Ranking
200 / 4616
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 6 analysts
Buy
Current Rating
5.750
Target Price
+234.30%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Pulmonx Corp Highlights

StrengthsRisks
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its solutions, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), is designed to treat severe emphysema patients. The StratX Platform is a cloud-based quantitative CT analysis service that offers physicians with a report that is designed for its solution, which includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation and has been validated in multiple randomized controlled clinical trials.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 56.14% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 83.79M.
Overvalued
The company’s latest PE is -1.19, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 36.47M shares, decreasing 14.14% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 3.23K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.32.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 7.50, which is higher than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 23.86M, representing a year-over-year increase of 14.80%, while its net profit experienced a year-over-year increase of 1.00%.

Score

Industry at a Glance

Previous score
7.50
Change
0

Financials

8.04

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

6.77

Operational Efficiency

9.35

Growth Potential

6.11

Shareholder Returns

7.21

Pulmonx Corp's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 8.73, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -1.19, which is -11.17% below the recent high of -1.06 and -668.77% above the recent low of -9.14.

Score

Industry at a Glance

Previous score
8.73
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 88/210
No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

The company’s current earnings forecast score is 7.67, which is lower than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Pulmonx Corp is 4.50, with a high of 14.00 and a low of 2.50.

Score

Industry at a Glance

Previous score
7.67
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts
Buy
Current Rating
5.750
Target Price
+234.30%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

110
Total
7
Median
9
Average
Company name
Ratings
Analysts
Pulmonx Corp
LUNG
6
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
32
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
30
1
2
3
...
22

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 6.20, which is lower than the Healthcare Equipment & Supplies industry's average of 6.82. Sideways: Currently, the stock price is trading between the resistance level at 2.55 and the support level at 1.18, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.21
Change
-0.01

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(2)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
0.025
Buy
RSI(14)
48.979
Neutral
STOCH(KDJ)(9,3,3)
14.435
Oversold
ATR(14)
0.243
High Vlolatility
CCI(14)
-21.926
Neutral
Williams %R
86.861
Oversold
TRIX(12,20)
0.329
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(3)
Neutral(0)
Buy(3)
Indicators
Value
Direction
MA5
1.802
Sell
MA10
1.770
Buy
MA20
1.687
Buy
MA50
1.699
Buy
MA100
2.048
Sell
MA200
3.842
Sell

Institutional Confidence

Currency: USD Updated: 2025-11-05

The company’s current institutional recognition score is 7.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.40. The latest institutional shareholding proportion is 89.51%, representing a quarter-over-quarter decrease of 8.42%. The largest institutional shareholder is PRIMECAP Management, holding a total of 5.16M shares, representing 12.68% of shares outstanding, with 9.20% decrease in holdings.

Score

Industry at a Glance

Previous score
7.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
PRIMECAP Management Company
Star Investors
5.16M
-4.62%
Fidelity Management & Research Company LLC
4.23M
-10.25%
Morgan Stanley & Co. LLC
2.94M
+0.27%
BlackRock Institutional Trust Company, N.A.
2.45M
-3.48%
The Vanguard Group, Inc.
Star Investors
2.29M
+0.51%
Deerfield Management Company, L.P.
1.89M
--
BNP Paribas Asset Management USA, Inc.
1.17M
-6.66%
Millennium Management LLC
1.17M
+459.54%
DWS Investments UK Limited
1.13M
-0.55%
Silvercrest Asset Management Group LLC
930.56K
--
1
2

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 1.60, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 0.22. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
1.60
Change
0
Beta vs S&P 500 index
0.22
VaR
+6.65%
240-Day Maximum Drawdown
+83.62%
240-Day Volatility
+108.59%

Return

Best Daily Return
60 days
+26.92%
120 days
+26.92%
5 years
+32.23%
Worst Daily Return
60 days
-8.67%
120 days
-41.59%
5 years
-60.94%
Sharpe Ratio
60 days
+0.84
120 days
-0.70
5 years
-0.55

Risk Assessment

Maximum Drawdown
240 days
+83.62%
3 years
+89.69%
5 years
+97.55%
Return-to-Drawdown Ratio
240 days
-0.86
3 years
-0.29
5 years
-0.20
Skewness
240 days
-0.37
3 years
-0.13
5 years
-1.58

Volatility

Realised Volatility
240 days
+108.59%
5 years
+85.17%
Standardised True Range
240 days
+20.15%
5 years
+59.89%
Downside Risk-Adjusted Return
120 days
-84.48%
240 days
-84.48%
Maximum Daily Upside Volatility
60 days
+179.49%
Maximum Daily Downside Volatility
60 days
+65.69%

Liquidity

Average Turnover Rate
60 days
+1.58%
120 days
+1.25%
5 years
--
Turnover Deviation
20 days
+131.88%
60 days
+61.01%
120 days
+27.21%

Peer Comparison

Healthcare Equipment & Supplies
Pulmonx Corp
Pulmonx Corp
LUNG
6.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
Castle Biosciences Inc
CSTL
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
TCMD
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
Artivion Inc
AORT
8.51 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI